EBQ:HACA: Difference between revisions
Ostermayer (talk | contribs) |
Ostermayer (talk | contribs) No edit summary |
||
| Line 22: | Line 22: | ||
==Major Points== | ==Major Points== | ||
*Therapeutic Hypothermia, define as deliberate cooling of a patient to 32-33.9°C (90-93F) who has no return of spontaneous neurologic activity after cardiac arrest. The goal is to reduce the repercussion injury to the brain which may be related to free radical formation, micro and macro circulation disruption and protease activation. At therapeutic temperatures the disruption of inflammatory and damaging cascades within the brain are thought to be decreased. <ref name="Cochrane">Arrich J, Holzer M, Herkner H, Müllner M. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database of Systematic Reviews 2009. PMID</ref> | |||
The HACA Trial (Hypothermia after Cardiac Arrest) randomized patients after witness Ventricular Fibrillation (VF) and pulseless Ventricular Tachycardia (VT) to 32-34°C Hypothermia. There was a significant patient centered outcome and 6 month mortality decrease in the hypothermia group. A later trial by [[Bernard Hypothermia Trial|Bernard et. al.]] demonstrated similar benefit and subsequent Cochrane reviews and the [[EBQ:TTM Trial|TTM Trial]] (33°C vs 33°C) found similar mortality and morbidity benefits.<ref name="Cochrane"></ref> | |||
*Standard care established by the ACCF/AHA 2013 guidelines, recommend therapeutic hypothermia for any comatose patient with a STEMI and out of hospital cardiac arrest from VF or puleless VT<ref>http://www.ncbi.nlm.nih.gov/pubmed/23256913</ref> | |||
==Study Design== | ==Study Design== | ||
*Randomized, Multicenter, unblinded treatment with blinded final outcome assessment. | |||
*N=275 | |||
**Normothermia control group (n=138) | |||
**Hypothermia treatment group (n=137) | |||
==Population== | ==Population== | ||
*Emergency Department enrollment | |||
===Patient Demographics=== | ===Patient Demographics=== | ||
===Inclusion Criteria=== | ===Inclusion Criteria=== | ||
| Line 53: | Line 61: | ||
==Funding== | ==Funding== | ||
==See Also== | |||
*[[Therapeutic Hypothermia]] | |||
*[[EBQ:TTM Trial|TTM Trial]] | |||
==Sources== | ==Sources== | ||
Revision as of 13:48, 1 October 2014
incomplete Journal Club Article
Holzer M, et al. "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest". The New England Journal of Medicine. 2002. 346(8):549-556.
PubMed Full text PDF
PubMed Full text PDF
Clinical Question
Does mild hypothermia improve neurologic outcomes compared with standard care normothermia in patients surviving ventricular fibrillation or pulseless ventricular tachycardic arrest?
Conclusion
In patients who have been successfully resuscitated after cardiac arrest due to ventricular fibrillation, therapeutic mild hypothermia increased the rate of a favorable neurologic outcome and reduced mortality
Major Points
- Therapeutic Hypothermia, define as deliberate cooling of a patient to 32-33.9°C (90-93F) who has no return of spontaneous neurologic activity after cardiac arrest. The goal is to reduce the repercussion injury to the brain which may be related to free radical formation, micro and macro circulation disruption and protease activation. At therapeutic temperatures the disruption of inflammatory and damaging cascades within the brain are thought to be decreased. [1]
The HACA Trial (Hypothermia after Cardiac Arrest) randomized patients after witness Ventricular Fibrillation (VF) and pulseless Ventricular Tachycardia (VT) to 32-34°C Hypothermia. There was a significant patient centered outcome and 6 month mortality decrease in the hypothermia group. A later trial by Bernard et. al. demonstrated similar benefit and subsequent Cochrane reviews and the TTM Trial (33°C vs 33°C) found similar mortality and morbidity benefits.[1]
- Standard care established by the ACCF/AHA 2013 guidelines, recommend therapeutic hypothermia for any comatose patient with a STEMI and out of hospital cardiac arrest from VF or puleless VT[2]
Study Design
- Randomized, Multicenter, unblinded treatment with blinded final outcome assessment.
- N=275
- Normothermia control group (n=138)
- Hypothermia treatment group (n=137)
Population
- Emergency Department enrollment
Patient Demographics
Inclusion Criteria
Exclusion Criteria
Interventions
Outcomes
Primary Outcome
Secondary Outcomes
Subgroup analysis
Criticisms & Further Discussion
Funding
See Also
Sources
- ↑ 1.0 1.1 Arrich J, Holzer M, Herkner H, Müllner M. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database of Systematic Reviews 2009. PMID
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/23256913